Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04779385
Status:
COMPLETED
Last Update Posted:
2021-05-05
First Post:
2021-02-26
Brief Title:
Cost and Effectiveness of Pressurized Intraperitoneal Aerosol Chemotherapy in Patients With Peritoneal Carcinoma
Sponsor:
University Hospital Grenoble
Organization:
University Hospital Grenoble
Study Overview
Official Title:
Cost and Effectiveness of Pressurized Intraperitoneal Aerosol Chemotherapy PIPAC in Patients With Peritoneal Carcinoma
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PIPAC-GRE
Brief Summary:
The presence of peritoneal carcinomatosis indicates a neoplastic disease evolved Without intervention the prognosis is poor with survival of only a few months Standard treatment is based on systemic chemotherapy however the pharmacokinetics of drug delivery to the peritoneum is poor with limited efficacy compared to other metastatic sites such as the liver or lung When the carcinomas are is resectable selected patients can benefit from targeted therapeutic approaches combining peritonectomy and Hyperthermic Intraperitoneal Chemotherapy HIPEC offering a significant improvement in survival A new surgical technique has been developed for patients with unresectable Chemotherapy intraperitoneal aerosol spray PIPAC The objective is to improve the survival time quality of life but can also make PC resectable and therefore accessible to complete excisional surgery The cost of this treatment is not yet fully assessed in France The main objective of this study is to assess the real cost of PIPAC in order to allow its dissemination
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None